Tipranavir receives European marketing approval

This article is more than 19 years old. Click here for more recent articles on this topic

European marketing approval has been granted for tipranavir, Boehringer Ingelheim’s protease inhibitor.

The drug will be marketed under the trade name Aptivus and has already received approval by regulatory authorities in the United Sates.

A non-peptidic protease inhibitor tipranavir is approved for use with a low, boosting dose of ritonavir in combination of other anti-HIV drugs in patients who have extensive previous experience of antiretroviral therapy and have HIV which is resistant to other protease inhibitors.

Glossary

drug interaction

A risky combination of drugs, when drug A interferes with the functioning of drug B. Blood levels of the drug may be lowered or raised, potentially interfering with effectiveness or making side-effects worse. Also known as a drug-drug interaction.

treatment-experienced

A person who has previously taken treatment for a condition. Treatment-experienced people may have taken several different regimens before and may have a strain of HIV that is resistant to multiple drug classes.

fusion inhibitor

Anti-HIV drug targeting the point where HIV locks on to an immune cell.

boosting agent

Booster drugs are used to ‘boost’ the effects of protease inhibitors and some other antiretrovirals. Adding a small dose of a booster drug to an antiretroviral makes the liver break down the primary drug more slowly, which means that it stays in the body for longer times or at higher levels. Without the boosting agent, the prescribed dose of the primary drug would be ineffective.

Food and Drug Administration (FDA)

Regulatory agency that evaluates and approves medicines and medical devices for safety and efficacy in the United States. The FDA regulates over-the-counter and prescription drugs, including generic drugs. The European Medicines Agency performs a similar role in the European Union.

Tipranavir is taken in two daily doses of 500mg together with 200mg of ritonavir.

Regulatory approval for tipranavir was granted on the basis of the RESIST I and RESIST II studies. These trials involved over 1400 individuals with heavy experience of antiretroviral treatment. Investigators found that patients who were treated with tipranavir were more likely than individuals taking a comparator protease inhibitor to achieve a response to treatment.

Last week the US Food and Drug Administration issued revised HIV treatment guidelines stating that patients with multi-drug experience should receive anti-HIV therapy with the aim of suppressing viral load as low as possible. In order to achieve this, the guidelines suggest that patients should consider taking a boosted protease inhibitor such as tipranavir/ritonavir together with the fusion inhibitor, T-20 (enfuvirtide, Fuzeon).

The current UK guidelines, issued by the British HIV Association note that the “RESIST-I and II studies provide data that the [protease inhibitor] tipranavir is an active agent for the management of drug-resistant HIV in highly treatment-experienced patients”, and notes that the use of tipranavir along with another active drug, use as T-20 significantly increases the chances of virological suppression.

Side-effects of tipranavir include raised liver enzymes and increased levels of blood fats. Most patients experiencing these side-effects in the RESIST studies did not need to change treatment. Tipranavir is known to interact with other protease inhibitors and with some drugs used to treat infections, such as fluconazole and rifampicin. It can also interact with statins and antacids requiring the dose of tipranavir to be increased.